Market Share And AdoptionHaving both Xiidra and Miebo in the portfolio could be a competitive advantage for Bausch + Lomb, with Miebo holding a significant share of the dry eye market prescriptions shortly after its launch.
Product PerformanceMiebo launch is performing well, with current trends indicating it is ahead of its sales plan, contributing positively to the company's overall performance.
Revenue GrowthRevenue growth observed across all three segments: Vision Care, Surgical, and Pharmaceuticals, with management expecting the trend to continue reflecting a 12-14% increase on a constant currency basis.